ArticleFrontiers in oncology2022

Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysis.

Jesse M Tettero et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.